The invention provides methods of treating diseases characterized by elevated expression of IL-17 or IL-23 in a mammalian subject, comprising administering to said subject an effective amount of an antagonist of IL-17 and IL-23, including diseases such as multiple sclerosis (MS), chronic inflammation, autoimmune diabetes, rheumatoid arthritis (RA) and other arthritic conditions, asthma, systhemic